Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 389 participants.
Also called NCT01193101
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 389 participants
- Sponsor
- Registry
-
NCT01193101
-
- Other papers using this trial's data
- Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China, Japan, South Korea, Taiwan, Thailand
- Registry status
- Completed
Technical summary
Registry record NCT01193101. Randomized; double masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2011-04 (actual). Results posted on 2015-08-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension
- Condition
- Hypertension
- Intervention (Drug)
- LCZ696
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01193101- Content hash
8bf0bd237d5afdf5354b3d64f9301e724cbcd932ec969a51625cf6779fa3aaf2